Table 3.
Results of the Markov cohort model for patients with high microsatellite instability endometrial cancer.
N = 1500 each cohort | Pembrolizumab/Lenvatinib | Carboplatin/Paclitaxel |
---|---|---|
Respond (n) | 380 | 488 |
Progress (n) | 692 | 187 |
Death (n) | 427 | 826 |
Cost ($) | 362,335 | 48,848 |
Difference in costs | 313,487 | |
Effectiveness (QALY) | 1.79 | 1.68 |
Incremental effectiveness (QALY) | 0.11 | |
ICER ($) | 2,849,882 |